In BC, while the interventional SWOG‐S0500 trial (NCT00382018) failed to show a benefit of CTCs count guided intervention versus physician's choice at disease progression,57 the METABREAST STIC CTC randomized clinical trial (NCT01710605) carried out more recently demonstrated that in hormone receptor‐positive, ERBB2‐negative metastatic BC, CTC count could be used as a reliable marker to guide the decision making for the choice between endocrine therapy and chemotherapy as the first‐line treatment.58 This evidence concerns the gene NR4A1 and breast cancer.